TNSN06370A1 - Derives de pyrimidine pour le traitement d'une croissance cellulaire anormale - Google Patents

Derives de pyrimidine pour le traitement d'une croissance cellulaire anormale

Info

Publication number
TNSN06370A1
TNSN06370A1 TNP2006000370A TNSN06370A TNSN06370A1 TN SN06370 A1 TNSN06370 A1 TN SN06370A1 TN P2006000370 A TNP2006000370 A TN P2006000370A TN SN06370 A TNSN06370 A TN SN06370A TN SN06370 A1 TNSN06370 A1 TN SN06370A1
Authority
TN
Tunisia
Prior art keywords
dans
des
anormale
traitement
une
Prior art date
Application number
TNP2006000370A
Other languages
English (en)
French (fr)
Inventor
Lu
John Charles Kath
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34966230&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TNSN06370(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of TNSN06370A1 publication Critical patent/TNSN06370A1/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
TNP2006000370A 2004-05-14 2006-11-13 Derives de pyrimidine pour le traitement d'une croissance cellulaire anormale TNSN06370A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57131204P 2004-05-14 2004-05-14
PCT/IB2005/001201 WO2005111023A1 (en) 2004-05-14 2005-05-02 Pyrimidine derivatives for the treatment of abnormal cell growth

Publications (1)

Publication Number Publication Date
TNSN06370A1 true TNSN06370A1 (fr) 2008-02-22

Family

ID=34966230

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2006000370A TNSN06370A1 (fr) 2004-05-14 2006-11-13 Derives de pyrimidine pour le traitement d'une croissance cellulaire anormale

Country Status (27)

Country Link
EP (1) EP1751143A1 (ru)
JP (1) JP4099212B2 (ru)
KR (1) KR100886990B1 (ru)
CN (2) CN102127058A (ru)
AP (1) AP2241A (ru)
AR (1) AR049097A1 (ru)
AU (2) AU2005243397A1 (ru)
BR (1) BRPI0511138A (ru)
CA (1) CA2566707A1 (ru)
CR (1) CR8749A (ru)
EA (1) EA200601796A1 (ru)
EC (1) ECSP066997A (ru)
GE (1) GEP20104875B (ru)
GT (1) GT200500113A (ru)
IL (1) IL178828A0 (ru)
MA (1) MA28583B1 (ru)
MX (1) MXPA06011890A (ru)
NL (2) NL1029045C2 (ru)
NO (1) NO20064576L (ru)
NZ (1) NZ550448A (ru)
PA (1) PA8632601A1 (ru)
PE (1) PE20060240A1 (ru)
TN (1) TNSN06370A1 (ru)
TW (1) TWI303635B (ru)
UY (1) UY28894A1 (ru)
WO (1) WO2005111023A1 (ru)
ZA (1) ZA200608394B (ru)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2566531A1 (en) * 2004-05-18 2005-12-15 Rigel Pharmaceuticals, Inc. Cycloalkyl substituted pyrimidinediamine compounds and their uses
US20070032514A1 (en) * 2005-07-01 2007-02-08 Zahn Stephan K 2,4-diamino-pyrimidines as aurora inhibitors
JP4332590B2 (ja) * 2005-12-21 2009-09-16 ファイザー・プロダクツ・インク 異常細胞増殖を治療するためのピリミジン誘導体
CN103951658B (zh) * 2007-04-18 2017-10-13 辉瑞产品公司 用于治疗异常细胞生长的磺酰胺衍生物
CN101903357A (zh) * 2007-07-17 2010-12-01 里格尔药品股份有限公司 作为pkc抑制剂的环状胺取代的嘧啶二胺
JP2011505407A (ja) * 2007-12-03 2011-02-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 過剰な又は異常な細胞増殖を特徴とする疾患を治療するためのジアミノピリジン
HUE035029T2 (en) * 2008-05-21 2018-03-28 Ariad Pharma Inc Kinase inhibitor phosphorus derivatives
US8410126B2 (en) * 2009-05-29 2013-04-02 Boehringer Ingelheim International Gmbh Pyrimidine inhibitors of PKTK2
JP5539518B2 (ja) 2009-08-14 2014-07-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 2−アミノ−5−トリフルオロメチルピリミジン誘導体の位置選択的調製
US8933227B2 (en) 2009-08-14 2015-01-13 Boehringer Ingelheim International Gmbh Selective synthesis of functionalized pyrimidines
US20120244141A1 (en) 2010-09-28 2012-09-27 Boehringer Ingelheim International Gmbh Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors
JPWO2014174745A1 (ja) * 2013-04-26 2017-02-23 国立大学法人京都大学 Eg5阻害剤
CN109608444B (zh) * 2018-11-27 2022-02-11 中国药科大学 含异吲哚啉酮的erk抑制剂及其制备方法与用途
CN111732548B (zh) * 2020-06-11 2022-06-17 浙江大学 N2-氨甲酰芳环-2-氨基嘧啶类衍生物及其医药用途
WO2024140671A1 (zh) * 2022-12-29 2024-07-04 南京昕瑞再生医药科技有限公司 一种稠三环类衍生物、包含其的药物组合物及其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9721437D0 (en) * 1997-10-10 1997-12-10 Glaxo Group Ltd Heteroaromatic compounds and their use in medicine
AR042586A1 (es) 2001-02-15 2005-06-29 Sugen Inc 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa
WO2003030909A1 (en) 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
RS20060097A (en) * 2002-12-20 2008-11-28 Pfizer Products Inc., Pyrimidine derivatives for the treatment of abnormal cell growth
UA80767C2 (en) * 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth

Also Published As

Publication number Publication date
CN102127058A (zh) 2011-07-20
EP1751143A1 (en) 2007-02-14
NZ550448A (en) 2010-11-26
GEP20104875B (en) 2010-01-11
PA8632601A1 (es) 2006-06-02
JP4099212B2 (ja) 2008-06-11
CN1953974A (zh) 2007-04-25
IL178828A0 (en) 2007-03-08
MA28583B1 (fr) 2007-05-02
AR049097A1 (es) 2006-06-28
KR20070012477A (ko) 2007-01-25
NL1031845C2 (nl) 2006-11-23
PE20060240A1 (es) 2006-04-01
AP2241A (en) 2011-06-01
TW200539871A (en) 2005-12-16
GT200500113A (es) 2006-01-10
NL1029045C2 (nl) 2006-06-02
KR100886990B1 (ko) 2009-03-04
CR8749A (es) 2006-12-05
BRPI0511138A (pt) 2007-11-27
NO20064576L (no) 2006-11-07
ZA200608394B (en) 2008-05-28
EA200601796A1 (ru) 2007-04-27
UY28894A1 (es) 2005-12-30
WO2005111023A1 (en) 2005-11-24
TWI303635B (en) 2008-12-01
NL1029045A1 (nl) 2005-11-15
MXPA06011890A (es) 2006-12-14
ECSP066997A (es) 2007-02-28
CA2566707A1 (en) 2005-11-24
NL1031845A1 (nl) 2006-07-31
JP2007537234A (ja) 2007-12-20
AU2009238255A1 (en) 2009-12-03
AP2006003790A0 (en) 2006-10-31
AU2005243397A1 (en) 2005-11-24

Similar Documents

Publication Publication Date Title
TNSN06370A1 (fr) Derives de pyrimidine pour le traitement d'une croissance cellulaire anormale
MA31319B1 (fr) Dérivés de sulfonylamides destines au traitement d'une croissance cellulaire anormale
MA30075B1 (fr) Derives de pyrimidine pour le traitement d'une croissance cellulaire anormale
MA31466B1 (fr) Derives de benzimidazole
MA54327B1 (fr) Inhibiteurs de kras g12c
TNSN06358A1 (fr) Methyl-aryl-ou-heteroaryl-amides substitues
MA30526B1 (fr) Inhibiteurs de prolyle hydroxylase
TNSN02012A1 (fr) Derives de pyrimidine nouveaux inhibiteurs de mmp, et compositions les contenant
TNSN05249A1 (fr) Benzopyrannes utiles pour le traitement d'etats inflammatoires
TNSN06360A1 (fr) 4-phenylamino-quinazoline-6-yl-amides
TNSN07476A1 (fr) Derives de n-(pyridine -2- yl) - sulfonamide
MA30784B1 (fr) Derives phenyliques et utilisation de ceux-ci en tant qu'immunomodulateurs.
TNSN06347A1 (fr) Derives de morpholine
MA51204B1 (fr) Formes pharmaceutiques comprenant un inhibiteur de la kallicréine plasmatique
MA31419B1 (fr) Derives de pyridine
MA27561A1 (fr) Derives d'aminoindazoles et leur utilisation comme inhibiteurs de kinases
MA30428B1 (fr) Derives de dihydropyrazolopyrimidinones
TNSN08196A1 (fr) Derives de pyrazine
MA29377B1 (fr) Derives de la pyrimidine pour traitement de troubles a caractere hyperproliferatif
TNSN08306A1 (fr) Imidazoles substitutes et leur utilisation comme pesticides
ATE368031T1 (de) Neue gamma secretase inhibitoren
TNSN06386A1 (fr) Derives de tetraazabenzo [e] azulene et leurs analogues
MA34361B1 (fr) Dérivés de tétrahydro-pyrido-pyrimidine
TNSN06027A1 (fr) Derives de nicotinamide utiles comme inhibiteurs de pde4
TNSN08359A1 (fr) Derives d'amines